Alpine Immune Sciences Debt to Equity

The latest debt-to-equity ratio for ALPN is 0.06. That is below the Healthcare sector average of 0.27. Investors often review this figure alongside Alpine Immune Sciences's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, ALPN currently prints 0.06 for debt-to-equity ratio, while the sector average sits near 0.27. That is roughly 77.5% below the sector mean. Large gaps often invite a closer look at Alpine Immune Sciences's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.06 for Alpine Immune Sciences is not 'good' or 'bad' on its own. Compare it with the peer average (0.27) and with ALPN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting ALPN's debt-to-equity ratio (0.06), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Alpine Immune Sciences's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.